Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 4/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401527 | 1.00 | HTR6 (0.43) | HTR6GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL8133241 | 1.00 | HTR6 (0.43) | HTR6GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL8126480 | 0.90 | GRIA1 (0.38) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL8126477 | 0.90 | GRIA1 (0.38) | GRIA1GRIA2GRIA3GRIA4MAPT | |
| SCHEMBL8134971 | 0.90 | ALDH1A1 (0.43) | GRIA1GRIA2GRIA3GRIA4MEN1 | |
| SCHEMBL8134966 | 0.90 | ALDH1A1 (0.43) | GRIA1GRIA2GRIA3GRIA4MEN1 | |
| SCHEMBL8125744 | 0.89 | KMT2A (0.39) | HTR6GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL8125747 | 0.89 | KMT2A (0.39) | HTR6GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL8134328 | 0.89 | ALDH1A1 (0.36) | HTR6GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL8134340 | 0.89 | ALDH1A1 (0.36) | HTR6GRIA1GRIA2GRIA3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079529-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | PAINCEPTOR PHARMA CORPORATION (CA) | 2006-04-13 | — | — | US | claimed |
| US-20040142936-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | NEUROSEARCH A/S | 2004-07-22 | — | — | US | claimed |
| US-6727260-B2 | USING COMPOUNDS CAPABLE OF INHIBITING THE ACTIVITY OF A PROTON-GATED CATION CHANNEL IN THERAPY OR ALEVIATION OF DISEASES OR DISORDERS ASSOCIATED WITH, OR MEDIATED BY A DROP IN EXTRACELLULAR PH | NEUROSEARCH A/S (DK) | 2004-04-27 | — | — | US | claimed |
| US-20020058663-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | AROS PHARMA APS (DK) | 2002-05-16 | — | — | US | claimed |
| EP-1183025-A2 | INHIBITORS OF PROTON-GATED CATION CHANNELS AND THEIR USE IN THE TREATMENT OF ISCHAEMIC DISORDERS | NEUROSEARCH A/S (DK) | 2002-03-06 | — | — | EP | claimed |
| WO-2000071102-A2 | INHIBITORS OF PROTON-GATED CATION CHANNELS AND THEIR USE IN THE TREATMENT OF ISCHAEMIC DISORDERS | NEUROSEARCH A/S (DK) | 2000-11-30 | — | — | WO | claimed |
| EP-0781285-B1 | FUSED INDOLE AND QUINOXALINE DERIVATIVES, THEIR PREPARATION AND USE AS GLUTAMATE ANTAGONISTS | NEUROSEARCH AS (DK) | 2000-01-12 | — | — | EP | claimed |
| US-7632948-B2 | Method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives | NEUROSEARCH A/S (DK) | 2009-12-15 | — | — | US | disclosed |
| US-7632948-B2 | Method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives | NEUROSEARCH A/S (DK) | 2009-12-15 | — | — | US | disclosed |
| US-20080269230-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-10-30 | — | — | US | disclosed |
| US-7288653-B2 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-10-30 | — | — | US | disclosed |
| US-20060178391-A1 | Method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives | NEUROSEARCH A/S (DK) | 2006-08-10 | — | — | US | disclosed |
| US-20060079529-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | PAINCEPTOR PHARMA CORPORATION (CA) | 2006-04-13 | — | — | US | disclosed |
| WO-2004018466-A2 | A METHOD OF PREPARING ENANTIOMERS OF INDOLE-2,3-DIONE-3-OXIME DERIVATIVES | NEUROSEARCH A/S (DK) | 2004-03-04 | — | — | WO | disclosed |
| US-20020058663-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | AROS PHARMA APS (DK) | 2002-05-16 | — | — | US | disclosed |
| EP-1183025-A2 | INHIBITORS OF PROTON-GATED CATION CHANNELS AND THEIR USE IN THE TREATMENT OF ISCHAEMIC DISORDERS | NEUROSEARCH A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000071102-A2 | INHIBITORS OF PROTON-GATED CATION CHANNELS AND THEIR USE IN THE TREATMENT OF ISCHAEMIC DISORDERS | NEUROSEARCH A/S (DK) | 2000-11-30 | — | — | WO | disclosed |
| EP-0781285-B1 | FUSED INDOLE AND QUINOXALINE DERIVATIVES, THEIR PREPARATION AND USE AS GLUTAMATE ANTAGONISTS | NEUROSEARCH AS (DK) | 2000-01-12 | — | — | EP | disclosed |
| US-5801174-A | CEREBROVASCULAR DISORDERS | NEUROSEARCH A/S (DK) | 1998-09-01 | — | — | US | disclosed |
| WO-1996008495-A1 | FUSED INDOLE AND QUINOXALINE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1996-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079529-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | TRPV1, HVCN1, TRPM2 | HTR6 434/4885GRIA1 393/4885GRIA2 266/4885 |
| US-20080269230-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | TRPV1, HVCN1, TRPM2 | HTR6 434/4885GRIA1 393/4885GRIA2 266/4885 |
| US-20020058663-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | ASIC1, ASIC3, TRPM4 | HTR6 487/4885GRIA1 279/4885GRIA2 210/4885 |
| US-20060178391-A1 | Method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives | IDO2, IDO1, TPH2 | HTR6 62/4885GRIA1 1444/4885GRIA2 329/4885 |
| US-20040142936-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | TRPV1, HVCN1, TRPM2 | HTR6 434/4885GRIA1 393/4885GRIA2 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.